LLY

884.89

-0.43%↓

UNH

592.9

+0.06%↑

NVO

115.12

-1.12%↓

JNJ

160.5

-0.47%↓

ABBV

195.47

-0.72%↓

LLY

884.89

-0.43%↓

UNH

592.9

+0.06%↑

NVO

115.12

-1.12%↓

JNJ

160.5

-0.47%↓

ABBV

195.47

-0.72%↓

LLY

884.89

-0.43%↓

UNH

592.9

+0.06%↑

NVO

115.12

-1.12%↓

JNJ

160.5

-0.47%↓

ABBV

195.47

-0.72%↓

LLY

884.89

-0.43%↓

UNH

592.9

+0.06%↑

NVO

115.12

-1.12%↓

JNJ

160.5

-0.47%↓

ABBV

195.47

-0.72%↓

LLY

884.89

-0.43%↓

UNH

592.9

+0.06%↑

NVO

115.12

-1.12%↓

JNJ

160.5

-0.47%↓

ABBV

195.47

-0.72%↓

Начало・Списък с акции・ADMA Biologics Inc

ADMA Biologics Inc

Затворен

Сектор Здравеопазване

19.55 0.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.32

Максимум

19.95

Ключови измерители
By Trading Economics
Приходи	35M 18M
Продажби	8M 82M
EPS	0.08
Марж на печалбата	21.748
Служители	624
EBITDA	7.9M 24M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	-0.87 downside

Дивиденти
By Dow Jones
Следващи печалби	6.11.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-71M 4.4B
Предишно отваряне	19.4
Предишно затваряне	19.55

Настроения в новините

By Acuity

26%

74%

76 / 366 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

19.43 / 19.75 Подкрепа & съпротива

ADMA Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.10.2024 г., 23:13 ч. UTC

Придобивния, сливания и поглъщания

Westpac to Sell Remainder of Auto-Finance Business for Up to A$1.6 Billion

2.10.2024 г., 17:15 ч. UTC

Придобивния, сливания и поглъщания

Telecom Italia Gets Non-Binding Offer for Sparkle From Italian Government, Retelit

2.10.2024 г., 22:58 ч. UTC

Придобивния, сливания и поглъщания

Westpac to Sell Remainder of Auto-Finance Business for Up to A$1.6 Bln

2.10.2024 г., 22:44 ч. UTC

Пазарно говорене

Arcadium Lithium Growth Plans Push Out Amid Low Prices -- Market Talk

2.10.2024 г., 22:39 ч. UTC

Придобивния, сливания и поглъщания

Westpac: Deal Completes Divestment of its Auto Finance Business

2.10.2024 г., 22:39 ч. UTC

Придобивния, сливания и поглъщания

Westpac: Auto Finance Loan Deal Not Expected to Have Material Impact on Financial Statements

2.10.2024 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Westpac: Auto Finance Loan Deal Expected to Complete in First Half of 2025

2.10.2024 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Westpac: Auto Finance Loan Sale Valued at A$1.4 Bln-A$1.6 Bln

2.10.2024 г., 22:37 ч. UTC

Придобивния, сливания и поглъщания

Westpac: Selling Auto Finance Loan Book to Resimac

2.10.2024 г., 21:50 ч. UTC

Печалби

Nike Stock Dives. Why More Losses Wouldn't Be a Surprise. -- Barrons.com

2.10.2024 г., 21:00 ч. UTC

Пазарно говорене

Печалби

ESG Roundup: Market Talk

2.10.2024 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

2.10.2024 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.10.2024 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

2.10.2024 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Texas Pacific Land Corp: Acquires Permian Oil and Gas Mineral and Royalty Interests in Cash Transaction

2.10.2024 г., 20:15 ч. UTC

Топ новини

Dow Edges Higher; Oil Prices Rise Further -- WSJ

2.10.2024 г., 19:26 ч. UTC

Топ новини

OpenAI Nearly Doubles Valuation to $157 Billion in Funding Round -- 2nd Update

2.10.2024 г., 18:52 ч. UTC

Топ новини

OpenAI Nearly Doubles Valuation to $157 Billion in Funding Round -- Update

2.10.2024 г., 18:35 ч. UTC

Топ новини

OpenAI's Latest Funding Round Nearly Doubles Valuation to $157 Billion -- Barrons.com

2.10.2024 г., 18:27 ч. UTC

Топ новини

Значими събития в новините

Oil Prices Rise Further; Indexes Waver -- WSJ

2.10.2024 г., 18:14 ч. UTC

Топ новини

2nd Update - LVMH Took Over the Paris Olympics. Now It's Snagged Formula One. -- WSJ

2.10.2024 г., 18:07 ч. UTC

Топ новини

Update - LVMH Took Over the Paris Olympics. Now It's Snagged Formula One. -- WSJ

2.10.2024 г., 17:41 ч. UTC

Топ новини

Fed's Barkin Sees More Work to Do on Inflation -- Barrons.com

2.10.2024 г., 17:33 ч. UTC

Пазарно говорене

Печалби

Nike Far from Path Back to Healthy Growth -- Market Talk

2.10.2024 г., 17:15 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Humana, Nike, Tesla, Conagra, Joby Aviation, Caesars, and More -- Barrons.com

2.10.2024 г., 17:00 ч. UTC

Топ новини

OpenAI Nearly Doubles Valuation to $157 Billion in Funding Round -- WSJ

2.10.2024 г., 16:55 ч. UTC

Пазарно говорене

Canada Soft Landing Depends on Impact from Mortgage Resets, Immigration Curbs -- Market Talk

2.10.2024 г., 16:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.10.2024 г., 16:49 ч. UTC

Пазарно говорене

TD Revises Rate Outlook But Still Doesn't Envisage Half-Point Cuts -- Market Talk

2.10.2024 г., 16:48 ч. UTC

Пазарно говорене

Печалби

Downsizing Talk Filters Into Some Corporate Plans -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

ADMA Biologics Inc Прогноза

Ценова цел

By TipRanks

-0.87% надолу

12-месечна прогноза

Среден 19.33 USD -0.87%

Висок 20 USD

Нисък 18 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за ADMA Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на ADMA Biologics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

19.43 / 19.75Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There are no events.

All events are bullish.

Настроение

By Acuity

76 / 366 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ADMA Biologics Inc

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.